TC Biopharm (TCBP) Stock Price, News & Analysis

Company Overview

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Key Stats

• Today's Range: $0.50 to $1.54
• 50-Day Range: $0.68 to $0.68
• 52-Week Range: $0.50 to $160.00
• Volume: 5.33 million shs
• Average Volume: 160,544 shs
• Market Capitalization: $279.21 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.00
• Consensus Rating: Buy

TCBP Stock Analysis - Frequently Asked Questions

How have TCBP shares performed this year?

TC Biopharm's stock was trading at $10.32 at the start of the year. Since then, TCBP shares have decreased by 93.4% and is now trading at $0.6810.
View the best growth stocks for 2025 here.

When did TC Biopharm's stock split?

TC Biopharm shares reverse split on the morning of Monday, February 10th 2025.The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TC Biopharm IPO?

TC Biopharm (TCBP) raised $17 million in an IPO on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO.

How do I buy shares of TC Biopharm?

Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TC Biopharm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), Exxon Mobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP).

Company Calendar

• Today: 6/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCBP
• CIK: 1872812
• Web: www.tcbiopharm.com
• Phone: 44-14-1433-7557
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $48.00
• High Stock Price Target: $48.00
• Low Stock Price Target: $48.00
• Potential Upside/Downside: +6,948.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.12
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.76 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $519.58 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 410,000
• Free Float: 28,000
• Market Cap: $279.21 thousand
• Optionable: Not Optionable
• Beta: 0.01